All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fox Chase Cancer Center Graduate Student Billy Truong Recognized for Third Year in a Row With American Society of Hematology Abstract Achievement Award

January 3rd 2024

Fox Chase Cancer Center graduate student Billy Truong was awarded the American Society of Hematology Abstract Achievement Award for the third year in a row for his study on targeting substrate interactions of the ERK2 protein that drive myeloproliferative neoplasms.

Futility Analysis Ends Nivolumab and Relatlimab Evaluation in Pretreated MSS mCRC

January 3rd 2024

The phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer will be discontinued due to futility.

Paving the Path to Progress in Multiple Myeloma Research

January 3rd 2024

A fascination with laboratory research paired with hard work and dedication led to Nikhil C. Munshi, MD, becoming a pioneer in multiple myeloma treatment.

EMA Validates MAA for Repotrectinib in ROS1+ NSCLC and NTRK+ Solid Tumors

January 3rd 2024

The European Medicines Agency has validated its marketing authorization application for repotrectinib in adult patients with ROS1 TKI-naive or -pretreated locally advanced or metastatic non–small cell lung cancer harboring ROS1 fusions, as well as adult and pediatric patients with TKI-naive and pretreated NTRK-positive locally advanced or metastatic solid tumors.

When Will We Acknowledge Information Overload in Oncology?

January 2nd 2024

The goal in highlighting this development is to attempt to raise awareness of the critical issue of information overload and the need for multiple involved parties to actively and aggressively search for appropriate, effective, and fiscally rational solutions.

Redefining Research Practices in Search of a Cure

January 2nd 2024

Fernando Cabanillas, MD, a mentor and leader in the lymphoma field, is being recognized for his contributions to the hematologic oncology space.

FDA Issues Complete Response Letter to Sotorasib for KRAS G12C–Mutated NSCLC

January 2nd 2024

The FDA has issued a complete response letter to the supplemental new drug application seeking the full approval of sotorasib for patients with KRAS G12C–mutated non–small cell lung cancer.

Padmaja Sai, MD Honored as AdventHealth Humanitarian of the Year 2023

January 2nd 2024

Padmaja Sai, MD, medical oncologist and hematologist with Florida Cancer Specialists & Research Institute, was presented last week with the AdventHealth Foundation 2023 Humanitarian of the Year Award.

FDA Grants Fast Track Status to Aglatimagene Besadenovec Plus Valacyclovir for Pancreatic Cancer

January 2nd 2024

The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.

Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma

January 2nd 2024

The National Medical Products Administration of China has approved sugemalimab paired with fluorouracil and platinum-based chemotherapy for use in the frontline treatment of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

FCS Medical Oncologist and Hematologist Maen Hussein, MD Elected to Serve as FLASCO President

January 1st 2024

During the 2023 Florida Society of Clinical Oncology Fall Session, several Florida Cancer Specialists & Research Institute, LLC, physicians were elected to serve as executive committee officers and chairs for the nationally recognized advocacy group in the upcoming term.

Lung Specialist Finds His “Sweet Spot” at the Intersection of Medicine and Technology

January 1st 2024

David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.

FDA Approves Kidney Cancer Therapy After Dana-Farber-Led Research Shows Improved Outcomes for Patients with Advanced Disease

December 31st 2023

Belzutifan, a HIF-2α inhibitor, has been approved by the FDA for the treatment of patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and antiangiogenic therapies.

Knocking Expectations Out of the Park in the Search for a Cure

December 31st 2023

Dedication to his patients and the field of hematology spanning decades has led Stephen J. Forman, MD, to break down barriers for treating patients with leukemia and lymphoma.

Fox Chase Cancer Center’s Edna “Eti” Cukierman Named to Newly Created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research

December 30th 2023

Edna “Eti” Cukierman, PhD, has been appointed to the newly created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.

A Drive to Help Patients Launches a Career in Revolutionizing Prostate Cancer Care

December 29th 2023

Howard I. Scher, MD, took a passion for improving cancer care and patient outcomes in prostate cancer and turned it into an extraordinary and explosive field of clinical research.

UCSF Health’s Eric J. Small, MD, Elected ASCO President for 2025-2026 Term

December 29th 2023

The American Society of Clinical Oncology has elected Eric J. Small, MD, FASCO, to serve as its president for the term beginning in June 2025.

ASCO Special Report Outlines Progress in Reducing Cancer Disparities for LGBTQ+ Individuals

December 29th 2023

Charles S. Kamen, PhD, MPH, discusses key developments and efforts that are planned and underway to further the progress that has been observed in terms of increasing cancer equity in sexual and gender minority individuals.

Revisit the Top 5 OncLive On Air Episodes of 2023

December 29th 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.